Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
NCT00004694 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2015-03-25
Summary
OBJECTIVES:
I. Determine the safety and efficacy of inhaled and subcutaneously administered heparin in the treatment of hereditary angioedema.
Conditions
- Angioedema
Interventions
- DRUG
-
heparin
Sponsors & Collaborators
-
University of Iowa
lead OTHER
Principal Investigators
-
John M. Weiler · University of Iowa
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1994-01-31
- Completion
- 1998-09-30
More Related Trials
-
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
NCT02316353 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
NCT01832896 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
NCT01188564 ·Status: COMPLETED ·Phase: PHASE3
-
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
NCT00289211 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
NCT00097695 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
NCT01095497 ·Status: COMPLETED ·Phase: PHASE2
-
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
NCT05120830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT04618211 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
NCT02741596 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
NCT01457430 ·Status: COMPLETED ·Phase: PHASE4
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213 ·Status: RECRUITING ·Phase: PHASE3
-
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
NCT05047185 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
NCT07046806 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
NCT01253382 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
NCT02247739 ·Status: COMPLETED ·Phase: PHASE2
-
C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation
NCT01151735 ·Status: WITHDRAWN ·Phase: PHASE4
-
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
NCT01541423 ·Status: COMPLETED
-
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
NCT05695248 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
NCT02052141 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
NCT00912093 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
NCT02586805 ·Status: COMPLETED ·Phase: PHASE3